Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles - reuters.com

Pfizer and BioNTech have halted a U.S. clinical trial for a COVID-19 vaccine due to difficulties recruiting enough participants for the study. The companies did not disclose specific enrollment figures or the vaccine's development stage in the excerpt, but recruitment challenges have become common as interest in new COVID vaccines has declined in recent years. The halt underscores the shifting landscape of COVID vaccine development as public demand wanes and resources shift toward other health priorities. Both companies have maintained significant roles in pandemic vaccine supply, though newer shots have faced competition and lower uptake than earlier versions. The study's cancellation may signal broader challenges the industry faces in conducting coronavirus vaccine research without sustained public engagement.